Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZD-4190 is a compound that inhibits both the vascular endothelial growth factor receptor 2 (VEGFR2) and the epidermal growth factor receptor (EGFR) signaling pathways, utilized in cancer treatment.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 128.00 | |
2 mg | In stock | $ 192.00 | |
5 mg | In stock | $ 322.00 | |
10 mg | In stock | $ 483.00 | |
25 mg | In stock | $ 769.00 | |
50 mg | In stock | $ 1,050.00 | |
100 mg | In stock | $ 1,420.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 325.00 |
Description | ZD-4190 is a compound that inhibits both the vascular endothelial growth factor receptor 2 (VEGFR2) and the epidermal growth factor receptor (EGFR) signaling pathways, utilized in cancer treatment. |
In vitro | ZD4190 can prevent outgrowth of malignant cells when the tumour burden is below a critical threshold. |
In vivo | ZD4190 (100 mg/kg, p.o.) effectively delays MDA-MB-435 tumor growth in mice. In ZD4190-treated tumors, 18F-FPPRGD2 uptake has decreased significantly relative to baseline by 26.74 8.12% (p<0.05) on day 1 and by 41.19 6.63% (p<0.01) on day 3, then has returned to baseline on day 7. Tumor uptake of 18F-FLT has also decreased on both day 1 and day 3 after initiation of ZD4190 treatment. However, ZD4190 does not significantly change 18F-FDG uptake in tumors, compared with the control group. |
Animal Research | ZD4190 was administered by gavage suspended in 1% polysorbate 80 at 50 mg/kg 24 h after tumour cell implantation for a maximum of 22 days. Control rodents were gavaged with the vehicle only and a third group was untreated. In preliminary experiments, rodents were killed on alternate days so that the effect of ZD4190 on tumour outgrowth could be assessed and subsequently the treatment response was evaluated at day 9 or 22. At least five rodents were included in each treatment group. |
Molecular Weight | 459.27 |
Formula | C19H16BrFN6O2 |
CAS No. | 413599-62-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20.83 mg/mL (45.35 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ZD-4190 413599-62-9 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR VEGFR Inhibitor inhibit Vascular endothelial growth factor receptor Epidermal growth factor receptor ErbB-1 ZD4190 HER1 ZD 4190 inhibitor